ProCE Banner Activity

CE / CME

Clinical Case Studies in Nontuberculous Mycobacterial Lung Disease: Expert Insights on Best Practices

Video

Hear expert faculty discuss how to optimize therapeutic strategies for complex NTM lung disease cases using clinical practice guidelines and application of the latest scientific evidence.

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: November 22, 2023

Expiration: November 21, 2024

Share

Faculty

Charles L. Daley

Charles L. Daley, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections Department of Medicine
National Jewish Health
Denver, Colorado

Shannon Kasperbauer

Shannon Kasperbauer, MD

Associate Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado

Pamela J. McShane

Pamela J. McShane, MD

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
The University of Texas Health
Science Center at Tyler
Tyler, Texas

Provided by

Provided by Clinical Care Options, LLC. Produced in partnership with NTM Info & Research (NTMir).

ProCE Banner

Supporters

Supported by an educational grant from Insmed Incorporated.

Insmed Incorporated

Partners

NTMIR

ProCE Banner

Target Audience

This program is intended for infectious diseases physicians, pharmacists, nurse practitioners, physician assistants, and other healthcare providers who care for patients with NTM-LD.

Program Learning Goal

The goal of this activity is to improve the competence of HCPs in optimizing therapeutic strategies for complex NTM-LD cases based on clinical practice guidelines and application of the latest scientific data.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Employ timely and appropriate diagnostic strategies for patients presenting with symptoms consistent with NTM-LD

  • Develop NTM-LD therapeutic strategies that are guidelines-based and individualized to promote long-term adherence and minimize treatment-limiting toxicities 

  • Summarize advanced strategies for management of antimicrobial-resistant or treatment-refractory NTM-LD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Charles L. Daley, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections Department of Medicine
National Jewish Health
Denver, Colorado

Charles L. Daley, MD: consultant/advisor/speaker: AN2, AstraZeneca, Hyfe, Insmed, Lilly, MannKind, Matinas BioPharma, NobHill, Otsuka, Spero Therapeutics, Zambon; researcher: AN2, Bugworks, Insmed, Juvabis, Paratek.

Shannon Kasperbauer, MD

Associate Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado

Shannon Kasperbauer, MD: consultant/advisor/speaker: AN2, Insmed, Paratek; investigator: Renovion. 

Pamela J. McShane, MD

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
The University of Texas Health
Science Center at Tyler
Tyler, Texas

Pamela J. McShane, MD: researcher: AN2 Therapeutics, Armata, Boehringher Ingelheim, Electromed, Insmed, MannKind, Paratek, Renovian, Spero; data monitoring committee: GREAT-2; advisor: Boehringer Ingelheim, Insmed, Spero.

The planners and content peer reviewers from Clinical Care Options, LLC and NTM Info and Research do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 22, 2023, through November 21, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and NTM Info and Research (NTMir). Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-23-303-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.